Evidence map›Paper›PMID 41339312›Full record

ArticleNature communications2025

Development of a p62 biodegrader for autophagy targeted degradation.

Zacharias Thiel, David Marcellin, Carole Manneville, Benedikt Goretzki, Luca Egger, Rob Maher, Noémie Siccardi, Laura Torres, Alexandra Probst, Catrin S Müller and 20 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. MinimalRSC chemical biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Zacharias ThielDiscovery Sciences, Biomedical Research, Novartis, Basel, Switzerland. zacharias.thiel@novartis.com.
David MarcellinDiscovery Sciences, Biomedical Research, Novartis, Basel, Switzerland.
Carole MannevilleDiscovery Sciences, Biomedical Research, Novartis, Basel, Switzerland.
Benedikt GoretzkiDiscovery Sciences, Biomedical Research, Novartis, Basel, Switzerland.
Luca EggerDiscovery Sciences, Biomedical Research, Novartis, Basel, Switzerland.ORCID http://orcid.org/0009-0006-2345-121X
Rob MaherDiscovery Sciences, Biomedical Research, Novartis, Cambridge, MA, USA.
Noémie SiccardiDiscovery Sciences, Biomedical Research, Novartis, Basel, Switzerland.
Laura TorresOpen Innovation at Global Health Disease Area, Biomedical Research, Novartis, Emeryville, CA, USA.
Alexandra ProbstGlobal Health Disease Area, Biomedical Research, Novartis, Emeryville, CA, USA.
Catrin S MüllerDiscovery Sciences, Biomedical Research, Novartis, Basel, Switzerland.ORCID http://orcid.org/0009-0009-7057-7677
Nathalie GeorgeBiologics Research Center, Biomedical Research, Novartis, Basel, Switzerland.
Markus VogelBiologics Research Center, Biomedical Research, Novartis, Basel, Switzerland.
Sabine SinterhaufBiologics Research Center, Biomedical Research, Novartis, Basel, Switzerland.
Alexandra LavoisierBiologics Research Center, Biomedical Research, Novartis, Basel, Switzerland.
Ji-Young ChoiBiologics Research Center, Biomedical Research, Novartis, Basel, Switzerland.
Laurianne ForcellinoBiologics Research Center, Biomedical Research, Novartis, Basel, Switzerland.
Alexandro LandshammerDisease Area X, Biomedical Research, Novartis, Basel, Switzerland.ORCID http://orcid.org/0000-0001-5367-3303
Patrick HauckDiscovery Sciences, Biomedical Research, Novartis, Basel, Switzerland.
Celine BeDiscovery Sciences, Biomedical Research, Novartis, Basel, Switzerland.
Frédéric VillardDiscovery Sciences, Biomedical Research, Novartis, Basel, Switzerland.
Sascha GutmannDiscovery Sciences, Biomedical Research, Novartis, Basel, Switzerland.ORCID http://orcid.org/0000-0002-4242-8510
Marc MeyerDiscovery Sciences, Biomedical Research, Novartis, Basel, Switzerland.
Felix FreulerDiscovery Sciences, Biomedical Research, Novartis, Basel, Switzerland.
Alexandra HinnigerDiscovery Sciences, Biomedical Research, Novartis, Basel, Switzerland.
César FernándezDiscovery Sciences, Biomedical Research, Novartis, Basel, Switzerland.
Suzanne ChauDiscovery Sciences, Biomedical Research, Novartis, Basel, Switzerland.
Maude PatoorDiscovery Sciences, Biomedical Research, Novartis, Basel, Switzerland.
Gilles SansigDiscovery Sciences, Biomedical Research, Novartis, Basel, Switzerland.
Gabriel MitchellOpen Innovation at Global Health Disease Area, Biomedical Research, Novartis, Emeryville, CA, USA.ORCID http://orcid.org/0000-0001-7977-5316
Beat NyfelerDiscovery Sciences, Biomedical Research, Novartis, Basel, Switzerland. beat.nyfeler@novartis.com.ORCID http://orcid.org/0000-0003-0624-9571

Funding

Gates Foundation INV-010720
6 · The paper itself

Abstract

Autophagy-based targeted degradation offers a powerful complement to proteasomal degradation leveraging the capacity and versatility of lysosomes to degrade complex cargo. However, it remains unclear which components of the autophagy-lysosomal pathway are most effective for targeted degradation. Here, we describe two orthogonal induced-proximity strategies to identify autophagy effectors capable of degrading organelles and soluble targets. Recruitment of autophagy cargo receptors, ATG8-like proteins, or the kinases ULK1 and TBK1 is sufficient to trigger mitophagy, while only autophagy cargo receptors capable of self-oligomerization degrade soluble cytosolic proteins. We further report a single-domain antibody against p62 and its use as a heterobifunctional degrader to clear mitochondria. Fusing the p62 single-domain antibody to PINK1 enables selective targeting of damaged mitochondria. Our study highlights the importance of avidity for targeted autophagy and suggests that autophagy cargo receptors are attractive entry points for the development of heterobifunctional degraders for organelles or protein aggregates.

Indexed as

AutophagySequestosome-1 ProteinAnimalsAutophagy-Related Protein-1 HomologAutophagy-Related Protein 8 FamilyHEK293 CellsHeLa CellsHumansIntracellular Signaling Peptides and ProteinsLysosomesMitochondriaMitophagyProtein Serine-Threonine KinasesProteolysisAutophagy-Related Protein-1 HomologAutophagy-Related Protein 8 FamilyIntracellular Signaling Peptides and ProteinsProtein Serine-Threonine KinasesSequestosome-1 ProteinSQSTM1 protein, humanTBK1 protein, humanULK1 protein, human

Identifiers

PMID41339312
PMCPMC12675543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.